SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SPCX Stock Jumps Overnight: Trump Hails Musk As ‘Modern-Day Thomas Edison’ Days After POTUS Portfolio Bought SpaceX Bonds

Equity

Disclosures showed Trump’s portfolio bought up to $5 million in SpaceX bonds two days before his Aug.20 space-policy push.

SpaceX’s Debut Quarter Fails To Lift Off: Short Seller Chanos Flags Starship Forecast Cut — But Wall Street Still Sees Big Upside

Musk moved from targeting at least daily flights around August 2027 to weekly or twice-weekly launches next year.

SPCX Stock Climbs After Trump Discloses SpaceX Stake — Goldman Sees Musk’s Terafab Fueling A $281B Chip Boom 

The White House said independent institutions made the investment without Trump’s input.

SPCX Stock Slides Overnight: Musk Maps Falcon Wind-Down For Starship — Rare ‘Sell’ Call Sees 27% Downside

 Falcon’s retirement could worsen a global launch-capacity shortage as rivals struggle to scale.

SpaceX Stock Rises Overnight: Elon Musk’s Stake Tops $900B — But Billions In Shares Still Depend On ‘Extremely Crazy Good’ Outcomes 

Some vesting targets involve multitrillion-dollar valuations, space-based computing and a million-person Mars settlement.

SPCX Stock Eyes Another Green Week: Analyst Warns Traders To ‘Divorce’ SpaceX Rally From Fundamentals

Morningstar maintained its $62 fair-value estimate, implying about 58% downside, and rates SPCX stock one star.

SpaceX Stock Slips Overnight After 3-Day Rally — Here's Why Ron Baron Sees 40x Upside And ‘Hundreds Of Billions’ In Gains

Baron Capital’s $3 billion SpaceX investment was worth about $25 billion in June, and the firm wants to invest another $1 billion.

SPCX’s Streak Of Red Weeks Is Testing Bulls: Jim Cramer Calls It A '100-Year' Bet As IPO Lockup Expiration Arrives Today

Thursday’s lockup expiration could more than double SpaceX’s public float, with up to 912 million shares becoming eligible for sale.

Top-Performing Leveraged ETFs of July 

July's top leveraged ETFs delivered triple-digit gains as SpaceX, PayPal and Chinese tech drove outsized moves amid volatile markets.

SPCX Stock Extends Post-IPO Rout: Starship Launch Scrub Deepens Slide As Short Sellers Build $25B Bear Bet 

KeyBanc expects major stock unlocks beginning around Q2 earnings, potentially expanding tradable supply sharply.

Investment Managers Series Trust II - Tradr 2X Short SpaceX Daily ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Trump hailed Musk as a “modern-day Thomas Edison,” praising SpaceX’s rockets, astronaut missions and Starlink’s disaster-response role.</li><li>Trump also credited Musk with turning SpaceX AI into “one of the world’s leaders in superintelligence.”</li><li>The space policy targets over 1,000 annual U.S. launches and reentries by 2030 through faster permitting, environmental reviews and infrastructure development.</li></ul>Shares of Space Exploration Technologies Corp (SPCX) jumped 3% overnight late Thursday as U.S. President Donald Trump hailed CEO Elon Musk as a “modern-day Thomas Edison,” while newly released filings showed his portfolio bought up to $5 million in SpaceX bonds two days before a major space-policy push.<a href="https://stocktwits.com/symbol/SPCX">SPCX stock</a> fell 4% to $160.57 on Thursday but remained up 1% for the week, on track for a second straight weekly gain.&nbsp;<h2 class="st-heading-2">Trump Celebrates SpaceX And Musk</h2>At the White House Science &amp; Tech Innovation Summit, Trump hailed Musk as “one of the greatest technology founders to ever live,” crediting his genius and determination with turning science fiction into reality.Trump recounted how Musk founded SpaceX in 2002 with his life savings and overcame immense odds to develop the first privately built liquid-fueled rocket to reach orbit. “Nobody thought it was possible to do the things he’s doing,” he said.The president credited SpaceX with ending NASA’s dependence on foreign nations for astronaut transportation and congratulated the company on Crew-12’s safe return from the International Space Station earlier Thursday. He also praised Starship as the largest rocket in history, highlighting its midair catch for rapid reuse: “It’s the first time anyone’s ever seen anything quite like it.”Turning to Starlink, Trump celebrated the world’s largest communications satellite network and recalled asking Musk for emergency equipment during severe flooding in North Carolina. He said Musk delivered it within hours despite shortages, restoring communications to stranded communities. “Saved hundreds of lives in North Carolina. So I never forgot that experience,” Trump said.Trump also praised Tesla and Neuralink, saying Musk “turned SpaceX AI into one of the world’s leaders in superintelligence.” Trump closed with a personal tribute: “Elon is our modern-day Thomas Edison. And Elon, I want to congratulate you. You’re my friend and all of that. But you are a very, very special guy. Thank you very much, and congratulations, Elon. Thank you.”&nbsp;<h2 class="st-heading-2">Trump’s SpaceX Investment Timing In Focus</h2>Financial disclosures released Thursday showed that Trump’s portfolio purchased between $1,000,001 and $5 million in SpaceX senior unsecured bonds on Aug. 18. The bonds pay 5.35% interest and mature in July 2031. Two days later, Trump signed a national security presidential memorandum to enable over 1,000 launches and reentries on American soil annually by 2030.&nbsp;The policy directs federal agencies to expedite permitting and environmental reviews, improve launch scheduling, and encourage infrastructure development with private-sector partners. It also calls for identifying additional launch and reentry sites, which could benefit commercial operators such as SpaceX.&nbsp;The purchase was part of 517 August transactions disclosed in the filing. Trump’s portfolio also bought up to $25 million in Meta Platforms shares, up to $6 million in Microsoft stock and a smaller amount of Oracle shares. The tech investments came ahead of a White House gathering with Musk, Meta CEO Mark Zuckerberg and other AI executives last month, where Trump favored a lighter regulatory approach.<h2 class="st-heading-2">Musk’s ‘Super Crazy’ Vision For SpaceX</h2>Separately, Musk also shared his outlook for SpaceX’s long-term value on Thursday: “This will sound super crazy, but I see a path to SpaceX being worth orders of magnitude more than the current Earth economy.”The prediction came as SpaceX agreed to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/asts-stock-spacex-grain-spectrum-analyst-who-called-deal-ligado-next/cZD6eLuRBVI">acquire</a> Grain Management’s nationwide 800 MHz spectrum portfolio, subject to FCC approval and other conditions. The low-band frequencies would help Starlink Mobile reach phones inside buildings, complementing satellite capacity with terrestrial infrastructure as the company moves toward competing directly for U.S. wireless subscribers.&nbsp;The deal also comes ahead of a scheduled lockup expiration on Friday, when up to 328.4 million SpaceX shares become eligible for sale, potentially increasing selling pressure if holders choose to cash out.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About SPCX?</h2>On Stocktwits, retail sentiment for SPCX slipped to ‘bullish’ from ‘extremely bullish’ levels a day ago amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/spcx_ss_c63e4b5537.png" alt="spcx ss.png" width="632" height="338"><figcaption>SPCX sentiment and message volume as of October 8 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/CGENIC/message/666112147">said</a>, “$SPCX shares unlock tomorrow but you can see the dip getting eaten up. That means the demand is higher, especially after today’s drop. This is about to create a FOMO until the end of next week! $190-$200 lottos!”<stembedurl>https://stocktwits.com/CGENIC/message/666112147</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Maykinit/message/666106805">said</a>, “$SPCX even with the writing clearly on the wall, some folks are seemingly unable to read it. Buy SPCX every, single. Day. Hold. Done”<stembedurl>https://stocktwits.com/Maykinit/message/666106805</stembedurl>SPCX stock has declined 0.2% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/asts-stock-spacex-grain-spectrum-analyst-who-called-deal-ligado-next/cZD6eLuRBVI">ASTS Stock Slides After-Hours As SpaceX Snags Grain Spectrum: Analyst Who Called The Deal Says ‘Ligado Is Next’&nbsp;</a>

Tesla and SpaceX CEO Elon Musk (L) receives the National Medal of Science from U.S. President Donald Trump during the Golden Age of American Innovation Summit at the Institute of Peace on October 08, 2026 in Washington, DC. (Photo by Win McNamee/Getty Images)

Tradr 2X Short SpaceX Daily ETF

Leverage Shares 2x Long SPCX Daily ETF

Defiance Daily 2X Space ETF

Tradr 2X Long SpaceX Daily ETF

Defiance Daily Target 2X Long SpaceX ETF

SpaceX

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$17.00
Prev Close	$15.13
Open	$16.33
Dividend Yield	N/A
50-Day Moving Average	$15.34
Beta	N/A
Avg. Volume	1.35M
PE Ratio	N/A

52-Week High	$41.65
52-Week Low	$10.01
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

SPCG Fundamentals